Clinical Trial Update: Spironolactone in Adult Congenital Heart Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for spironolactone in adults with congenital heart disease and heart failure, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Endomyocardial Fibrosis
• Heart Failure

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Congenital Heart Disease, Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2019-08-21